Moodcenter_NYC

09/12/2019

08/08/2019

We are currently recruiting participants for FDA approved clinical trial research for:
- Intermittent Explosive Disorder,
- Tourette’s syndrome and
- Schizophrenia.

If you or anyone you know if affected by these disorders and want to know more about clinical trial research, please get in touch with the Mood Disorder Center.

Feel free to call us at 646-838-5111.

08/08/2019

The Psychiatric 'Wonder Drug' That Almost No One Is Using

https://www.vice.com/en_us/article/qvgdj3/the-psychiatric-wonder-drug-that-almost-no-one-is-using

Clozapine could save the lives of suicidal schizophrenic people who aren't responding to other treatments. So why are so few doctors using it?

07/25/2019

Rates of schizophrenia are generally similar from country to country—about .5% to 1 percent of the population (there are variations - but the variance is difficult to track due to differing measuring standards in many countries, etc.). Source: Dr. Robin Murray.
Another way to express the prevalence of schizophrenia at any give time is the number of individuals affected per 1,000 total population. In the United States that figure is 7.2 per 1,000. This means that a city of 3 million people will have over 21,000 individuals suffering from schizophrenia.

Incidence: The number of people who will be diagnosed as having schizophrenia in a year is about one in 4,000. So about 1.5 million people will be diagnosed with schizophrenia this year, worldwide. About 100,000 people in the United States will be diagnosed with schizophrenia this year.

[Note: The term 'prevalence' of Schizophrenia usually refers to the estimated population of people who are living with Schizophrenia at any given time. The term 'incidence' of Schizophrenia refers to the annual diagnosis rate, or the number of new cases of Schizophrenia diagnosed each year. ]

Prevalence of schizophrenia compared to other well-known diseases

Therefore, the approximate number of people in the United States suffering from:

Schizophrenia: Over 2.2 million people
Multiple Sclerosis: 400,000 people
Insulin-dependent Diabetes: 350,000 people
Muscular Dystrophy: 35,000 people

07/25/2019

Meet our Team🌟
Founder of MoodCenter: Dr. Faedda

Dr. Faedda is a clinical psychopharmacologist specializing in Mood Disorders. He has participated in NIMH-funded research on actigraphy-derived biomarkers for the differential diagnosis of childhood psychiatric disorders, co-chairs the International Society for Bipolar Disorder’s Taskforce on: ‘Prodromes of Bipolar Disorders’. His interests include child and adolescents’ mood, attention-deficit, anxiety and psychotic disorder, psychiatric phenotype of the Velo-Cardio-Facial Syndrome.

07/25/2019

MoodCenter is one of New York’s leading Clinical Research Sites, founded in 1991 by Dr. Faedda. We are located on 46th Street and 5th Avenue （2 West 46 Street，Suite 511）in Manhattan. We are currently conducting clinical trails for Tourette Syndrome, Schizophrenia and Intermittent Explosive Disorder. For more information about us and these clinical trials. Please visit our official website：www.mdcnyc.com

Welcome to New York Premiere Clinical Trials English/Español/Italiano/中文/Gujarati